Thiencynonate hydrochloride (N-methyl-9α-(3-azabicyclo[3,3,1]nonanyl)-2ʹ-cyclopentyl-2ʹ-hydroxyl-2ʹ-thienylacetate, I·HCl), an new muscarinic receptor antagonist, was synthesized and its enantiomers were obtained form the optical pure of demethylation product II. A convenient resolution method of demethylation product II has been developed with N-p-toluenesulfonylglutamic acid as the resolution reagent. The structures of I and II were elucidated by X-ray analysis.
INTRODUCTION
Design, development, and marketing of new chiral drugs are now a major theme in the drug chirality research and industry. 1 In 1996, the FDA announced it would consider further incentives for developing single isomer drugs for their better pharmacokinetics prosperity, safety, and tolerability. 2 Our recent drug candidate: N-MethylL-9α-(3-azabicyclo [3, 3 ,1]nonanyl)-2ʹ-cyclopentyl-2ʹ-hydroxyl-2ʹ-thienylacetate hydrochloride (Thiencynonate hydrochloride, I·HCl, Chart 1), is a potent selective M 1 antagonist. It is composed of a tertiary hydroxyl acid as a key component as like many of the muscarinic receptor antagonists. It exhibits classical antimuscarine side effects, such as dry mouth. The preliminary biology results suggest that the (S)-(-)-configuration of the tile compound display an improved therapeutic profile compared to its racemic counterpart. The optical resolution of racemates via diastereoisomeric salt formation is a common way for the preparation of optical isomers. 3, 4 We didn't found a suitable acid for the resolution of I due to the weak alkalescence of the tertiary N structure. In our efforts to have a production of the enantiopure, we synthesized the demethylation compound II to enhance the alkalescence. We found that inclusion crystallisation with N-p-toluenesulfonylglutamic acid(TSGA) as a chiral host is an effective method for the resolution of II with high enantiomeric excess.
EXPERIMENTAL General
All the reagents for syntheses were commercially available and used without further purification or purified by standard methods prior to use. Melting points were determined using a RY-1 apparatus and are uncorrected. Elemental analyses were performed on a Perkin-Elmer 240C analyzer. 1 H-NMR spectra were measured in CDCl 3 using a multinuclear FT-NMR spectrometer ARX300 (Bruker). Mass spectra were obtained from Micromass ZabSpec and API3000 instruments. The enantiomeric excess of the title compound was determined by HPLC. Condition of HPLC: Hypersil BDS column and β-cyclodextrin as chiral mobile phase additive, methanol: acetonitrile: KH 2 PO 4 (0.075mol⋅ L -1 ): H 2 O =25:2:60:18 as elute. α-Cyclopentyl-α-hydroxyl-α-thienylacetic acid was synthesized by addition of Grignard reagents to diethyl oxalate as described in the literature. Methyl α-cyclopentyl-α-hydroxyl-α-thienylacetate (2.6g, 11mmol) and 3-azabicyclo[3,3,1]nonan-9α-ol (1.5g, 10mmol) were dissolved in anhydrous n-heptane (100 mL), NaH(0.5g assay 80%) was added. The solution was reflux for 3 hours. The solvent was removed under reduced pressure; the residue was dissolved in ether (150 mL), washed with water and brine, dried over anhydrous sodium sulfate, and concentrated to dryness. I was purified by flashchromatography (chloroform/methanol, 9:1) and isolated as an oil (3.1g, 79% 
A mixture of I (3.6g, 10mmol) and 2,2,2-trichloroethylchloroformate(2.5 g, 12mmol) in 50mL anhydrous benzene was heated under reflux for 20 hours. After evaporation of the solvent and excessive 2,2,2-trichloroethylchloroform ate, the residual oil was added to a solution of 50mL of 25%~28% NH 3 ·H 2 O and 50mL of ether. The organic solution was washed with two 10mL portion of saturated brine, and dried over anhydrous magnesium sulfate. The solution evaporated under reduced pressure to give the product 4.7g (91% yield) as a yellow oil. 
9α-(3-azabicyclo[3,3,1]nonanyl)-2ʹ-cyclopentyl-2ʹ-hydroxyl-2ʹ-thienylacetate. rac-II
A solution of the yellow oil product in 50ml glacial HOAc and 3.5g Zinc dust was stirred for 5 hours at room temperature. After removal of the Zinc by filtration, the filtrate was basified with concentrated NaOH and extracted with three 50-ml portions of ether. The solution evaporated under reduced pressure to give rac-II 2. 
Optical resolution of rac-II
A solution of rac-II (3.5g, 10mmol) and L-N-toluenesulfonylglutamic acid (TSGA) (3.0g, 10mmol) in anhydrous ethanol (150mL) was kept at 50� for 12 h. After being cooled to room temperature, a 1:1 inclusion complex (S)-(-)-II·L-TSGA was obtained as colorless crystals. Recrystallization of the salts from ethanol three times gave pure inclusion crystals. The inclusion complex was basified with 2 mol⋅ L -1 NaOH and extracted with ether (50mL (
S)-(-)-I and (R)-(+)-I (S)-(+)-I and (R)-(-)-I were synthesized by methylation of enantiopure II. (R)-(+)-II or (S)-(-)
-II (0.97g, 2.8mmol) was dissolved in 30 mL anhydrous ethanol and 10 Ml anhydrous Et 2 O, 0.5mL CH 3 I (3.2mmol) and 1 g K 2 CO 3 were added. The mixture was stirred for 3 hours at room temperature. Additional 0.5 mL was added and then stirred for 24 hours. After removal of the K 2 CO 3 by filtration, the filtrate was evaporated under reduced pressure and purified by flash-chromatography (chloroform/methanol, 9:1). ( 
RESULTS AND DISCUSSION
Optical resolution of I was performed as outlined in Scheme 1. Racemate I can be conveniently synthesized by methyl α-cyclopentyl-α-hydroxyl-α-thienylacetate and 3-azabicyclo[3,3,1]nonan-9α-ol. In order to demethylate of I, carbamate would be desirable. 2,2,2-trichloroethyl carbamate can be removed with zinc dust in glacial HOAc at room temperature. 
Sheme 1.
The colorless crystals of (R)-(+)-II and (R)-(+)-I suitable for X-ray analysis were obtained by recrystallization from dichloromethane solution. The X-ray ORTEP structure of the two compounds with atomic labelling is shown in Fig. 1 . X-ray structure analytical data showed that the two compounds are similar composed of a 3-azabicyclo[3,3,1]nonane structure and a tertiary hydroxyl acid that adopted R-configuration. The bicyclic structure adopts a twin-chair conformation, this is the most favored conformation for the bicyclo[3,3,1]nonane ring system. 
